Bianca MENCHICCHI,Andreas HENSEL,Francisco Martin GOYCOOLEA VALENCIA
申请号：
MX2015006991
公开号：
MX2015006991A
申请日:
2015.06.01
申请国别(地区):
MX
年份:
2016
代理人:
摘要：
The present disclosure is related to antibiotic-free colloidal emulsions with an average diameter of <1 µm coated with polysaccharides and that are developed as potential new formulations against Helicobacter pylori (H. pylori), propionibacterium acne, Staphylococcus aureus, Pseudomonas aeruginosa, Porphyromonas gingivalis and Escherichia coli infections, by interfering with the cell adhesion mechanisms of the human stomach and therefore, preventing the occurrence of the infection and its recurrence. The present invention relates to the preparation of oil core nanoemulsions co-stabilized with lysozyme and lecithin. These primary colloidal emulsions have a net neutral electric charge allowing the consequent deposition of negatively charged polysaccharides without the need for the use of synthetic cationic surfactant. Coated colloidal emulsions were made by coating the colloidal emulsion with low or high molecular weight dextran sulfate. All formulations were also loaded with curcumin i n the oil core. These colloidal emulsions coated with polysaccharide are able to inhibit the adhesion of H. pylori to gastric cells at a certain dose, and increasing inhibition with low molecular weight dextran sulfate nanocapsules regarding to those of high molecular weight and the uncoated nanoemulsion. Furthermore, the antiadhesive activity of the colloidal emulsions coated with polysaccharide is much greater than solutions of dextran sulfate alone. Other anionic polysaccharides with anti-adhesion activity towards H. pylori can be used to prepare these nanocapsules (for example fucoidan, Ribes nigrum arabinogalactan or okra rhamnogalactorunan). These nanocapsules can be used as a treatment to prevent or aid in the treatment of H. pylori gastric infection.Emulsiones coloidales libres de antibiótico de diámetro promedio < 1 µm recubierto con polisacáridos se desarrollan como nuevas formulaciones potenciales contra la infección de Helicobacter pylori (H. pylori), propionibacterium acne
